Malignant Mesothelioma Market by Drug Type (Carboplatin, Cisplatin, Gemcitabine), Treatment Type (Chemotherapy, Immunotherapy, Targeted therapy), Route of Administration, Distribution - Global Forecast 2024-2030

Malignant Mesothelioma Market by Drug Type (Carboplatin, Cisplatin, Gemcitabine), Treatment Type (Chemotherapy, Immunotherapy, Targeted therapy), Route of Administration, Distribution - Global Forecast 2024-2030


The Malignant Mesothelioma Market size was estimated at USD 772.67 million in 2023 and expected to reach USD 834.43 million in 2024, at a CAGR 8.26% to reach USD 1,347.15 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Malignant Mesothelioma Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Malignant Mesothelioma Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Malignant Mesothelioma Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Corp., Argenx SE, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories, Eisai Co., Ltd., Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Karyopharm Therapeutics Inc., Merck & Co., Inc., Mylan N.V., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Novocure GmbH, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Polaris Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Ltd., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Malignant Mesothelioma Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type

Carboplatin

Cisplatin

Gemcitabine

Pemetrexed

Vinorelbine
Treatment Type

Chemotherapy
Local Chemotherapy
Systemic Chemotherapy

Immunotherapy

Targeted therapy
Route of Administration

Oral

Parenteral
Distribution

Hospitals Pharmacies

Online Pharmacies

Retail Pharmacies
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Malignant Mesothelioma Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Malignant Mesothelioma Market?
3. What are the technology trends and regulatory frameworks in the Malignant Mesothelioma Market?
4. What is the market share of the leading vendors in the Malignant Mesothelioma Market?
5. Which modes and strategic moves are suitable for entering the Malignant Mesothelioma Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Malignant Mesothelioma Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of malignant mesothelioma worldwide
5.1.1.2. Increase in the number of clinical trials for the treatment of malignant mesothelioma
5.1.1.3. Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
5.1.2. Restraints
5.1.2.1. High cost of malignant mesothelioma surgical treatment
5.1.3. Opportunities
5.1.3.1. Introduction of novel therapies for the treatment of malignant mesothelioma
5.1.3.2. Favorable funding landscape for research on malignant mesothelioma
5.1.4. Challenges
5.1.4.1. Adverse effects associated with the treatment of malignant mesothelioma
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Malignant Mesothelioma Market, by Drug Type
6.1. Introduction
6.2. Carboplatin
6.3. Cisplatin
6.4. Gemcitabine
6.5. Pemetrexed
6.6. Vinorelbine
7. Malignant Mesothelioma Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3.1. Local Chemotherapy
7.3.2. Systemic Chemotherapy
7.3. Immunotherapy
7.4. Targeted therapy
8. Malignant Mesothelioma Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Malignant Mesothelioma Market, by Distribution
9.1. Introduction
9.2. Hospitals Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Malignant Mesothelioma Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Malignant Mesothelioma Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Malignant Mesothelioma Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AbbVie Inc.
14.1.2. Advanz Pharma Corp.
14.1.3. Argenx SE
14.1.4. AstraZeneca Plc
14.1.5. Boehringer Ingelheim GmbH
14.1.6. Bristol-Myers Squibb Company
14.1.7. Cipla Limited
14.1.8. Dr. Reddy's Laboratories
14.1.9. Eisai Co., Ltd.
14.1.10. Eli Lilly and Company
14.1.11. Emcure Pharmaceuticals Limited
14.1.12. F. Hoffmann-La Roche Ltd.
14.1.13. Fresenius Kabi AG
14.1.14. Karyopharm Therapeutics Inc.
14.1.15. Merck & Co., Inc.
14.1.16. Mylan N.V.
14.1.17. Nichi-Iko Pharmaceutical Co., Ltd.
14.1.18. Novartis AG
14.1.19. Novocure GmbH
14.1.20. Ono Pharmaceutical Co. Ltd.
14.1.21. Pfizer Inc.
14.1.22. Polaris Pharmaceuticals, Inc.
14.1.23. Sanofi S.A.
14.1.24. Sun Pharmaceuticals Industries Ltd.
14.1.25. Wellona Pharma
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. MALIGNANT MESOTHELIOMA MARKET RESEARCH PROCESS
FIGURE 2. MALIGNANT MESOTHELIOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MALIGNANT MESOTHELIOMA MARKET DYNAMICS
FIGURE 7. MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 10. MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 14. MALIGNANT MESOTHELIOMA MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings